Pharma Industry

AbbVie’s IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn’s disease after getting approval for the new indication from the FDA. Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson &

Canadian wireless network carrier Telus has agreed a C$2.9 billion ($2.2 billion) deal to acquire LifeWorks, a digital health specialist that will bulk up the telecoms company’s Telus Health unit. Toronto-based LifeWorks provides cloud-based telehealth as well as in-person health services – with an emphasis on mental health and wellbeing – that employers can make

Walgreens is the latest US retail pharmacy giant to have a go at disrupting the clinical trials industry, with the launch of a new business unit that will tap into its reserve of patient data, as well as the ability to recruit patients across its retail network. The company says it plans to use a

AstraZeneca is rumoured to be considering a bid to take control of its longstanding partner Mereo BioPharma, according to a report in The Times, which doesn’t provide the source of the speculation. The UK-based but US-listed biotech licensed rights to AZ’s orally-active neutrophil elastase inhibitor alvelestat for the rare disease alpha-1 antitrypsin deficiency (AATD) five

A personalised, treatment plan for patients with breast cancer is the first digital health product to emerge from a newly-announced partnership between digital health specialist Sidekick and pharma group Eli Lilly. The two companies say the integrated digital therapeutic (DTx) for breast cancer will aim to promote behaviour modifications to improve the wellbeing of breast

Boehringer Ingelheim must like what it has seen in its two-year-old R&D collaboration with Trutino Biosciences to develop cytokine therapies – it has just taken an option to buy the company outright. The German pharma group originally teamed up with San Diego-based Trutino on a project to apply its drug discovery and development platform to

An alliance between Spanish drugmaker Almirall and digital health company Happify has yielded its first fruit, with the launch of their Claro app designed to reduce anxiety and improve wellbeing in people with psoriasis. The web-based app is rolling out first in the UK, Spain and Italy and is aimed at the 20% to 30%

SAE Media Group’s 2nd Annual Biosensors for Medical Wearables*In collaboration with Medical Design Briefs*24th – 25th October 2022 | Boston, MA, USASponsored by: Raumedichttp://www.biosensors-medical-wear.com/PharmaPhorum Advances in development and therapeutic applications of on-body sensorsSAE Media Group is proud to present the Biosensors for Medical Wearables Conference, taking place on the 24th – 25th October 2022. As

Around 425,000 people in England and Wales with cardiovascular disease who are at risk of a secondary stroke or heart attack, could be eligible for treatment with Amarin’s Vazkepa, following a NICE recommendation. In draft guidance, the health technology assessment (HTA) organisation has recommended Vazkepa (icosapent ethyl) as a treatment option for adult patients with

Pharma’s evolving role in patient care The digital revolution has already reshaped the commercial engine of biopharma companies. Pharma’s digital initiatives now routinely enable new channels that educate and market to patients, physician engagement that is more efficient and effective, and novel payment mechanisms and distribution models that improve access to therapies. The pandemic accelerated

Takeda has reported positive new, long-term results in its pivotal trial of dengue fever vaccine TAK-003 that builds the case for the shot as regulators review marketing applications. The new data – coming after four-and-a-half years of follow-up – has revealed that TAK-003 cut dengue-related hospitalisations by 84%, with 61% protective efficacy against symptomatic dengue

Digital health funding has grown exponentially over the last few years and fuelled significant investment. Payers, healthcare professionals (HCPs) and patients recognise the positive impact these digital tools can have either standalone or in conjunction with therapeutic intervention. For instance, earlier last month Pfizer and Sidekick Health launched a new dermatitis app aimed at improving

The UK medicines regulator has awarded Alnylam’s RNAi-based therapy zilebesiran for hypertension an ‘innovation passport‘, a designation designed to speed up NHS access to promising new medicines. The passport means that LentiGlobin will be reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA) via the new innovative licensing and access pathway (ILAP) introduced in

Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. This post makes a case for encouraging and supporting presenters in order to get the most out of their expertise. Has this happened to

American entrepreneur and investor Mark Cuban tells us why he and his partners launched the Mark Cuban Cost Plus Drug Company (MCCPDC), a public-benefit corporation and online pharmacy that provides patients access to medications at a lower cost.  US drug prices have soared over the last several decades, causing, at times, financial hardship for patients

For the first time since 2019, the American Society of Clinical Oncology (ASCO) annual meeting will be an in-person conference. We’re excited to re-connect with fellow oncology and clinical care professionals from across the globe to learn from one another and discuss key advances in cancer care and research. From innovations in cancer therapeutics to

R&D into orphan drugs is growing alongside the number of approved treatments, providing treatments for rare diseases that previously did not have any. However, Ben Hargreaves finds that the blockbuster success that certain treatments are achieving is beginning to raise questions over whether healthcare systems can afford this in the long-term. In 1983, the US

Jan Deman is Takeda’s head of digital customer experience for Europe and Canada. But he’d prefer not to refer to what he does as “innovation”. It’s a word, he says, that doesn’t reflect where pharma stands in relation to larger trends. “It’s not innovation in the usual sense of the word,” Deman says. “Mostly it

In the healthcare sector and beyond, the adoption of digital tools and novel analytics has exploded. However, unlike many consumer industries, biopharma, medical technology, and wellness companies have struggled to build meaningful personalized customer experiences. Today, biopharma and med tech executives are faced with numerous channels, novel technologies, and a high volume of data. They struggle

GlaxoSmithKline is due to complete the split from its consumer health decision – now renamed Haleon – next month, with a listing for the new company on the London Stock Exchange set for 18 July. GSK said it has now filed a prospectus for the submission of Haleon’s ordinary shares to the stock market with the